ArteraAI is NOT Recommended in NCCN Guidelines
ArteraAI does not appear in any NCCN Clinical Practice Guidelines for Prostate Cancer or Prostate Cancer Early Detection. The NCCN guidelines do not mention, recommend, or reference ArteraAI as a diagnostic, prognostic, or risk stratification tool for prostate cancer management 1, 2, 3.
What the NCCN Guidelines Actually Recommend for Prostate Cancer Diagnostics
The NCCN guidelines provide specific recommendations for diagnostic testing in prostate cancer, but ArteraAI is absent from all versions reviewed:
For Early Detection and Screening:
- PSA testing remains the primary screening tool, with consideration of percent free PSA, 4Kscore, or phi for risk refinement when PSA is in the 4-10 ng/mL range 1
- Digital rectal examination (DRE) should be performed in patients with elevated PSA 1, 4
- Multiparametric MRI may help identify regions of cancer and guide biopsy decisions 1
For Biopsy Guidance:
- Extended-pattern TRUS-guided biopsy with 10-12 cores targeting the peripheral zone is the standard approach 1, 4
- Transition zone biopsy may be considered in repeat biopsies if PSA remains persistently elevated 1
For Risk Stratification:
- The NCCN relies on clinical staging (T stage), Gleason score, and PSA levels to stratify patients into risk categories (very low, low, intermediate, high, very high) 1, 2, 3
- Germline and somatic genetic testing is recommended in specific clinical scenarios 5
Why This Matters
The NCCN guidelines represent the recognized standard for cancer care throughout the world and are developed through critical review of evidence by multidisciplinary expert panels 6. If ArteraAI were validated and recommended for clinical use, it would appear in these guidelines. The absence of ArteraAI from NCCN recommendations spanning from 2010 through 2026 indicates it is not part of the evidence-based standard of care 1, 2, 3.
Clinical Implications
For prostate cancer diagnosis and risk stratification, clinicians should rely on the established tools explicitly recommended in NCCN guidelines: PSA testing with refinement tools (percent free PSA, 4Kscore, phi), DRE, multiparametric MRI, and histopathologic assessment via systematic biopsy 1, 4. Any emerging diagnostic technology not yet incorporated into NCCN guidelines should be considered investigational until sufficient evidence supports its inclusion in consensus-driven recommendations 6.